https://cms.syndax.com/publication/pediatric-preclinical-testing-consortium-evaluation-of-the-menin-inhibitor-vtp-50469-against-xenograft-models-of-mll-rearranged-infant-acute-lymphoblastic-leukemia/ 2018-04-03T10:00:36+00:00 https://cms.syndax.com/publication/vtp50469-is-a-novel-orally-available-menin-mll1-inhibitor-effective-against-mll-rearranged-and-npm1c-leukemia-2/ 2018-04-18T10:00:08+00:00 https://cms.syndax.com/publication/targeting-the-menin-mll1-interaction-site-as-a-treatment-for-mixed-lineage-leukemia-rearranged-mll-r-and-npm1c-aml-2/ 2018-07-28T10:00:39+00:00 https://cms.syndax.com/publication/mll-menin-inhibition-reverses-pre-leukemic-progenitor-self-renewal-induced-by-npm1-mutations-and-prevents-aml-development/ 2018-12-04T10:00:26+00:00 https://cms.syndax.com/publication/targeting-epigenetic-mechanisms-to-reverse-stem-cell-programs-in-cancer/ 2018-12-18T10:00:12+00:00 https://cms.syndax.com/publication/vtp50469-is-a-novel-orally-available-menin-mll1-inhibitor-effective-against-mll-rearranged-and-npm1c-leukemia/ 2018-12-22T10:00:09+00:00 https://cms.syndax.com/publication/targeting-the-menin-mll1-interaction-site-as-a-treatment-for-mixed-lineage-leukemia-rearranged-mll-r-and-npm1c-aml/ 2019-01-31T10:00:25+00:00 https://cms.syndax.com/publication/a-first-in-class-menin-mll1-antagonist-for-the-treatment-of-mll-r-and-npm1-mutant-leukemias/ 2020-04-29T10:00:35+00:00 https://cms.syndax.com/publication/safety-and-efficacy-of-menin-inhibition-in-patients-with-mll-rearranged-and-npm1-mutant-acute-leukemia-a-phase-1-first-in-human-study-of-sndx-5613/ 2021-12-30T10:00:30+00:00 https://cms.syndax.com/publication/the-menin-inhibitor-revumenib-sndx-5613-leads-to-durable-responses-in-patients-with-kmt2a-rearranged-or-npm1-mutant-aml-updated-results-of-a-phase-1-study/ 2022-12-23T10:00:24+00:00 https://cms.syndax.com/publication/outcomes-after-transplant-in-relapsed-refractory-kmt2ar-mllr-and-mnpm1-npm1c-leukemia-patients-achieving-remissions-after-menin-inhibition-revumenib-sndx-5613-ph1-experience/ 2022-12-30T10:00:30+00:00 https://cms.syndax.com/publication/characterization-of-acquired-resistance-mutations-to-menin-inhibitors/ 2023-04-28T10:00:33+00:00 https://cms.syndax.com/publication/menin-inhibition-in-pediatric-kmt2ar-leukemia-phase-1-and-expanded-access-experience-with-revumenib/ 2023-05-31T10:00:23+00:00 https://cms.syndax.com/publication/revumenib-in-patients-with-acute-leukemias-compassionate-use-program-experience/ 2023-06-30T10:00:33+00:00 https://cms.syndax.com/publication/early-results-of-the-phase-i-ii-study-investigating-the-all-oral-combination-of-the-menin-inhibitor-revumenib-sndx-5613-with-decitabine-cedazuridine-astx727-and-venetoclax-in-acute-myeloid-leukemi/ 2023-12-14T20:46:12+00:00 https://cms.syndax.com/publication/revumenib-maintenance-therapy-following-revumenib-induced-remission-and-transplant/ 2023-12-18T10:00:24+00:00 https://cms.syndax.com/publication/revumenib-monotherapy-in-patients-with-relapsed-refractory-kmt2ar-acute-leukemia-efficacy-and-safety-results-from-the-augment-101-phase-1-2-study-2/ 2023-12-20T10:00:42+00:00 https://cms.syndax.com/publication/revumenib-monotherapy-in-patients-with-relapsed-refractory-kmt2ar-acute-leukemia-topline-efficacy-and-safety-results-from-the-pivotal-augment-101-phase-2-study-3/ 2023-12-22T10:00:03+00:00 https://cms.syndax.com/publication/phase-1-2-evaluation-of-revumenib-in-patients-with-advanced-colorectal-cancer-and-other-solid-tumors/ 2024-01-10T20:43:06+00:00 https://cms.syndax.com/publication/safety-and-efficacy-of-axatilimab-in-patients-with-chronic-graft-versus-host-disease-agave-201/ 2024-02-23T10:00:41+00:00 https://cms.syndax.com/publication/pivotal-phase-2-results-of-augment-101-for-revumenib-in-kmt2ar-acute-leukemia-pediatric-experience/ 2024-04-08T10:00:03+00:00 https://cms.syndax.com/publication/axatilimab-for-chronic-graft-versus-host-disease-responses-in-fibrosis-dominant-organs-in-agave-201-2/ 2024-04-26T10:00:32+00:00 https://cms.syndax.com/publication/revumenib-monotherapy-in-patients-with-relapsed-refractory-kmt2ar-acute-leukemia-efficacy-and-safety-results-from-the-augment-101-phase-1-2-study/ 2024-04-30T10:00:05+00:00 https://cms.syndax.com/publication/axatilimab-for-chronic-graft-versus-host-disease-responses-in-fibrosis-dominant-organs-in-agave-201-3/ 2024-05-31T10:00:10+00:00 https://cms.syndax.com/publication/safety-and-activity-of-revumenib-in-combination-with-fludarabine-cytarabine-fla-in-patients-with-relapsed-refractory-acute-leukemias/ 2024-06-07T10:00:44+00:00 https://cms.syndax.com/publication/characterization-of-immunophenotypic-changes-following-menin-inhibition-in-acute-myeloid-leukemia/ 2024-06-20T20:39:47+00:00 https://cms.syndax.com/publication/revumenib-monotherapy-in-patients-with-relapsed-refractory-kmt2ar-acute-leukemia-topline-efficacy-and-safety-results-from-the-pivotal-augment-101-phase-2-study-2/ 2024-06-21T10:00:05+00:00 https://cms.syndax.com/publication/phase-1b-study-of-azacitidine-venetoclax-and-revumenib-in-newly-diagnosed-older-adults-with-npm1-mutated-or-kmt2a-rearranged-aml-interim-results-of-dose-escalation-from-the-beat-aml-consortium/ 2024-06-28T10:00:44+00:00 https://cms.syndax.com/publication/axatilimab-for-chronic-graft-versus-host-disease-responses-in-fibrosis-dominant-organs-in-agave-201/ 2024-06-28T10:00:59+00:00 https://cms.syndax.com/publication/pharmacokinetics-and-exposure-response-analyses-of-revumenib-support-dosing-in-a-broad-population-of-patients-with-relapsed-refractory-acute-leukemias/ 2024-09-04T10:00:44+00:00 https://cms.syndax.com/publication/efficacy-and-safety-of-axatilimab-at-3-different-doses-in-patients-with-chronic-graft-versus-host-disease-cgvhd-and-related-bronchiolitis-obliterans-syndrome-bos-results-of-a-pivotal-phase-2-stud/ 2024-09-20T10:00:50+00:00 https://cms.syndax.com/publication/revumenib-monotherapy-in-patients-with-relapsed-refractory-kmt2ar-acute-leukemia-topline-efficacy-and-safety-results-from-the-pivotal-augment-101-phase-2-study/ 2024-09-27T10:00:31+00:00 https://cms.syndax.com/publication/exposure-response-relationships-for-axatilimab-a-humanized-monoclonal-antibody-targeting-csf-1r-in-patients-with-chronic-graft-versus-host-disease-2/ 2024-10-18T10:00:54+00:00 https://cms.syndax.com/publication/evaluation-of-clinical-trial-efficacy-endpoints-in-chronic-graft-versus-host-disease/ 2024-10-31T10:00:05+00:00 https://cms.syndax.com/publication/population-pharmacokinetics-poppk-of-revumenib-in-patients-with-relapsed-refractory-acute-leukemias/ 2024-11-05T10:00:02+00:00 https://cms.syndax.com/publication/revumenib-physiologically-based-pharmacokinetic-pbpk-model-for-evaluation-of-age-effect-and-cyp3a4-mediated-drug-drug-interaction-ddi-in-relapsed-refractory-acute-leukemias/ 2024-11-23T10:00:02+00:00 https://cms.syndax.com/publication/revumenib-as-pre-emptive-therapy-for-measurable-residual-disease-in-npm1-mutated-or-kmt2a-rearranged-aml-a-domain-of-the-multi-arm-allg-amlm26-intercept-platform-trial/ 2024-12-03T10:00:02+00:00 https://cms.syndax.com/publication/phase-i-ii-study-of-the-all-oral-combination-of-revumenib-sndx-5613-with-decitabine-cedazuridine-astx727-and-venetoclax-save-in-r-r-aml/ 2024-12-10T10:00:01+00:00 https://cms.syndax.com/publication/dynamics-of-overall-and-organ-specific-responses-to-axatilimab-in-chronic-graft-versus-host-disease-analysis-from-the-agave-201-study/ 2024-12-16T10:00:04+00:00 https://cms.syndax.com/publication/exposure-response-relationships-for-axatilimab-a-humanized-monoclonal-antibody-targeting-csf-1r-in-patients-with-chronic-graft-versus-host-disease/ 2024-12-19T10:00:04+00:00 https://cms.syndax.com/publication/updated-results-and-longer-follow-up-from-the-augment-101-phase-2-study-of-revumenib-in-all-patients-with-relapsed-or-refractory-r-r-kmt2ar-acute-leukemia/ 2024-12-20T10:00:01+00:00 https://cms.syndax.com/publication/a-multi-site-break-through-cancer-trial-phase-ii-study-investigating-dual-inhibition-of-bcl2-and-menin-in-aml-mrd-using-the-combination-of-venetoclax-and-revumenib-trial-in-progress/ 2024-12-21T10:00:01+00:00 https://cms.syndax.com/publication/axatilimab-abrogates-inflammatory-cytokines-and-chemokines-and-interrupts-the-differentiation-of-monocytes-to-macrophages-a-pathogenic-driver-of-inflammation-and-fibrosis-in-cgvhd/ 2024-12-21T10:00:20+00:00 https://cms.syndax.com/publication/real-world-patient-characteristics-and-treatment-patterns-in-patients-with-chronic-graft-versus-host-disease-receiving-belumosudil-in-the-united-states/ 2025-02-10T19:16:06+00:00 https://cms.syndax.com/publication/the-effects-of-prior-lines-of-therapy-on-clinical-outcomes-for-patients-with-chronic-graft-versus-host-disease-receiving-axatilimab-a-post-hoc-analysis-of-agave-201/ 2025-02-18T19:12:35+00:00 https://cms.syndax.com/publication/kinetics-and-management-of-hepatic-laboratory-elevations-associated-with-axatilimab-in-the-agave-201-study/ 2025-02-26T19:08:55+00:00 https://cms.syndax.com/publication/axatilimab-for-patients-with-dermatologic-manifestations-of-chronic-graft-versus-host-disease-a-post-hoc-analysis/ 2025-03-12T19:06:33+00:00 https://cms.syndax.com/publication/updated-results-and-longer-follow-up-from-the-augment-101-phase-2-study-of-revumenib-in-all-patients-with-relapsed-or-refractory-r-r-kmt2ar-acute-leukemia-2/ 2025-04-04T19:00:19+00:00 https://cms.syndax.com/publication/updated-results-and-longer-follow-up-from-the-augment-101-phase-2-study-of-revumenib-in-all-patients-with-relapsed-or-refractory-r-r-kmt2ar-acute-leukemia-french/ 2025-04-08T18:40:25+00:00 https://cms.syndax.com/publication/safety-considerations-for-axatilimab-among-patients-with-chronic-graft-versus-host-disease-in-the-agave-201-study/ 2025-04-23T14:39:38+00:00 https://cms.syndax.com/publication/dynamics-of-overall-and-organ-specific-responses-to-axatilimab-in-chronic-graft-versus-host-disease-analysis-from-the-agave-201-study-2/ 2025-05-06T19:51:14+00:00 https://cms.syndax.com/publication/the-effects-of-prior-lines-of-therapy-on-clinical-outcomes-for-patients-with-chronic-graft-versus-host-disease-receiving-axatilimab-a-post-hoc-analysis-of-agave-201-2/ 2025-05-06T19:51:20+00:00 https://cms.syndax.com/publication/correlations-of-clinician-reported-responses-with-other-response-measures-in-patients-with-chronic-graft-versus-host-disease-an-analysis-from-the-agave-201-trial/ 2025-05-06T19:51:44+00:00 https://cms.syndax.com/publication/axatilimab-abrogates-inflammatory-cytokines-and-chemokines-and-interrupts-the-differentiation-of-monocytes-to-macrophages-a-pathogenic-driver-of-inflammation-and-fibrosis-in-cgvhd-2/ 2025-05-06T19:51:49+00:00 https://cms.syndax.com/publication/phenotypic-changes-in-systemic-immune-cells-in-response-to-axatilimab-in-healthy-male-japanese-volunteers/ 2025-05-06T19:51:57+00:00 https://cms.syndax.com/publication/real-world-treatment-patterns-of-patients-with-chronic-graft-versus-host-disease-who-received-3-or-more-lines-of-treatment-in-the-united-states/ 2025-05-06T19:52:01+00:00 https://cms.syndax.com/publication/real-world-patient-characteristics-and-treatment-patterns-in-patients-with-chronic-graft-versus-host-disease-receiving-belumosudil-in-the-united-states-2/ 2025-05-06T19:52:07+00:00 https://cms.syndax.com/publication/axatilimab-for-treatment-of-patients-with-ocular-chronic-graft-versus-host-disease-a-post-hoc-analysis-of-the-phase-2-agave-201-study/ 2025-05-09T13:46:32+00:00 https://cms.syndax.com/publication/budget-impact-analysis-of-revumenib-for-the-treatment-of-relapsed-or-refractory-acute-leukemias-with-a-kmt2a-translocation-in-the-united-states/ 2025-05-20T18:39:51+00:00 https://cms.syndax.com/publication/axatilimab-in-patients-with-lung-chronic-graft-versus-host-disease-and-related-bronchiolitis-obliterans-syndrome-results-from-the-agave-201-study/ 2025-05-22T12:52:21+00:00 https://cms.syndax.com/publication/the-effects-of-prior-lines-of-therapy-on-clinical-outcomes-for-patients-with-chronic-graft-versus-host-disease-receiving-axatilimab-a-post-hoc-analysis-of-agave-201-3/ 2025-05-23T13:11:06+00:00 https://cms.syndax.com/publication/correlations-of-clinician-reported-responses-with-other-response-measures-in-patients-with-chronic-graft-versus-host-disease-an-analysis-from-the-agave-201-trial-2/ 2025-05-28T21:43:11+00:00 https://cms.syndax.com/publication/a-novel-modeling-approach-for-predicting-the-time-course-of-antidrug-antibodies-of-biologics-application-to-axatilimab-as-an-example/ 2025-06-02T22:01:37+00:00 https://cms.syndax.com/publication/axalap-phase-ib-study-of-axatilimab-in-combination-with-olaparib-in-brca1-2-and-palb2-associated-metastatic-her2-negative-breast-cancer/ 2025-06-03T19:13:44+00:00 https://cms.syndax.com/publication/updated-results-and-longer-follow-up-from-the-augment-101-phase-2-study-of-revumenib-in-all-patients-with-relapsed-or-refractory-r-r-kmt2ar-acute-leukemia-3/ 2025-06-12T06:02:57+00:00 https://cms.syndax.com/publication/patients-with-relapsed-or-refractory-r-r-nucleophosmin-1-mutated-npm1m-acute-myeloid-leukemia-aml-updated-results-from-the-phase-2-augment-101-study/ 2025-06-12T06:04:04+00:00 https://cms.syndax.com/publication/revumenib-activity-in-patients-with-nup98r-acute-leukemia-results-from-the-augment-101-phase-1-study/ 2025-06-12T06:04:58+00:00 https://cms.syndax.com/publication/azacitidine-venetoclax-and-revumenib-for-newly-diagnosed-older-adults-with-acute-myeloid-leukemia-aml-and-npm1-mutation-or-kmt2a-rearrangement-updated-results-from-the-beat-aml-consortium/ 2025-06-12T06:06:13+00:00 https://cms.syndax.com/publication/dynamics-of-overall-and-organ-specific-responses-to-axatilimab-in-chronic-graft-versus-host-disease-analysis-from-the-agave-201-study-3/ 2025-06-12T06:09:09+00:00 https://cms.syndax.com/publication/the-effects-of-prior-lines-of-therapy-on-clinical-outcomes-for-patients-with-chronic-graft-versus-host-disease-receiving-axatilimab-a-post-hoc-analysis-of-agave-201-4/ 2025-06-12T06:09:22+00:00 https://cms.syndax.com/publication/correlations-of-clinician-reported-responses-with-other-response-measures-in-patients-with-chronic-graft-versus-host-disease-an-analysis-from-the-agave-201-trial-3/ 2025-06-12T06:10:01+00:00 https://cms.syndax.com/publication/trial-in-progress-a-randomized-open-label-phase-3-study-of-axatilimab-versus-best-available-therapy-in-patients-with-chronic-graft-versus-host-disease-after-%e2%89%a52-prior-lines-of-systemic-thera/ 2025-06-12T06:11:25+00:00 https://cms.syndax.com/publication/inhibition-of-csf1r-csf1-axis-with-axatilimab-effectively-targets-leukemia-stem-cells-and-monocytes-in-bh3-mimetics-resistant-aml/ 2025-06-12T16:15:43+00:00 https://cms.syndax.com/publication/revumenib-activity-in-patients-with-nup98r-acute-leukemia-results-from-the-augment-101-phase-1-study-2/ 2025-09-08T13:28:05+00:00 https://cms.syndax.com/publication/patients-with-relapsed-or-refractory-r-r-nucleophosmin-1-mutated-npm1m-acute-myeloid-leukemia-aml-updated-results-from-the-phase-2-augment-101-study-2/ 2025-09-08T13:28:19+00:00 https://cms.syndax.com/publication/updated-results-and-longer-follow-up-from-the-augment-101-phase-2-study-of-revumenib-in-all-patients-with-relapsed-or-refractory-r-r-kmt2ar-acute-leukemia-al/ 2025-09-08T13:28:34+00:00 https://cms.syndax.com/publication/a-phase-3-study-of-revumenib-plus-azacitidine-venetoclax-in-adult-patients-with-newly-diagnosed-npm1-mutated-or-kmt2a-rearranged-acute-myeloid-leukemia-aml-ineligible-for-intensive-chemotherapy-evo/ 2025-10-15T21:07:26+00:00 https://cms.syndax.com/publication/updated-results-and-longer-follow-up-from-the-augment-101-phase-2-study-of-revumenib-in-all-patients-with-relapsed-or-refractory-r-r-kmt2ar-acute-leukemia-al-2/ 2025-10-20T21:19:11+00:00 https://cms.syndax.com/publication/exposure-response-relationships-for-axatilimab-in-patients-with-chronic-graft-versus-host-disease/ 2025-10-22T19:15:53+00:00 https://cms.syndax.com/publication/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-axatilimab-in-healthy-japanese-male-participants-results-from-a-phase-1-randomized-double-blind-dose-escalation-study/ 2025-10-22T19:16:31+00:00 https://cms.syndax.com/publication/axatilimab-in-recurrent-or-refractory-chronic-graft-versus-host-disease-2/ 2025-10-22T19:17:15+00:00 https://cms.syndax.com/publication/safety-and-efficacy-of-axatilimab-at-3-different-doses-in-patients-with-chronic-graft-versus-host-disease-agave-201/ 2025-10-22T19:18:01+00:00 https://cms.syndax.com/publication/safety-tolerability-and-efficacy-of-axatilimab-a-colony-stimulating-factor-1-receptor-csf-1r-humanized-antibody-in-advanced-chronic-graft-versus-host-disease-related-bronchiolitis-obliterans-syn/ 2025-10-22T19:18:45+00:00 https://cms.syndax.com/publication/phase-1-study-of-axatilimab-sndx-6352-a-csf-1r-humanized-antibody-for-chronic-graft-versus-host-disease-after-2-or-more-lines-of-systemic-treatment/ 2025-10-22T19:20:40+00:00 https://cms.syndax.com/publication/safety-tolerability-and-efficacy-of-axatilimab-a-csf-1r-humanized-antibody-for-chronic-graft-versus-host-disease-after-2-or-more-lines-of-systemic-treatment/ 2025-10-22T19:21:01+00:00 https://cms.syndax.com/publication/sndx-6352-0502-a-phase-1-open-label-dose-escalation-trial-to-investigate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamic-activity-of-axatilimab-sndx-6352-monotherapy-in-pa/ 2025-10-22T19:23:42+00:00 https://cms.syndax.com/publication/sndx-6352-0502-a-phase-1-open-label-dose-escalation-trial-to-investigate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamic-activity-of-sndx-6352-in-combination-with-durvalumab-in-patie/ 2025-10-22T19:25:54+00:00 https://cms.syndax.com/publication/targeting-colony-stimulating-factor-1-receptor-csf-1r-with-sndx-6352-a-novel-anti-csf-1r-targeted-antibody/ 2025-10-22T19:27:17+00:00 https://cms.syndax.com/publication/axatilimab-for-chronic-graft-versus-host-disease-after-failure-of-at-least-two-prior-systemic-therapies-results-of-a-phase-i-ii-study/ 2025-10-22T19:27:48+00:00 https://cms.syndax.com/publication/first-in-human-single-ascending-dose-study-in-healthy-volunteers-of-sndx-6352-a-humanized-igg4-monoclonal-antibody-targeting-colony-stimulating-factor-1-receptor-csf-1r/ 2025-10-22T19:28:25+00:00 https://cms.syndax.com/publication/azacitidine-venetoclax-and-revumenib-for-newly-diagnosed-npm1-mutated-or-kmt2a-rearranged-aml/ 2025-10-22T19:39:54+00:00 https://cms.syndax.com/publication/treatment-patterns-in-patients-with-relapsed-or-refractory-npm1-mutated-npm1m-acute-myeloid-leukemia-aml-in-the-united-states-us-real-world-data-analysis/ 2025-10-22T19:40:18+00:00 https://cms.syndax.com/publication/trial-in-progress-a-phase-1-study-of-revumenib-intensive-chemotherapy-in-patients-with-newly-diagnosed-acute-myeloid-leukemia-harboring-genetic-alterations-in-kmt2a-npm1-or-nup98-sndx-5613-0708/ 2025-10-22T19:40:59+00:00 https://cms.syndax.com/publication/budget-impact-analysis-of-revumenib-for-the-treatment-of-relapsed-or-refractory-acute-leukemias-with-a-kmt2a-translocation-in-the-united-states-2/ 2025-10-22T19:41:49+00:00 https://cms.syndax.com/publication/menin-inhibition-with-revumenib-for-npm1-mutated-relapsed-or-refractory-acute-myeloid-leukemia-the-augment-101-study/ 2025-10-22T19:42:21+00:00 https://cms.syndax.com/publication/menin-inhibition-with-revumenib-for-kmt2a-rearranged-relapsed-or-refractory-acute-leukemia-augment-101/ 2025-10-22T19:44:13+00:00 https://cms.syndax.com/publication/targeting-of-epigenetic-co-dependencies-enhances-anti-aml-efficacy-of-menin-inhibitor-in-aml-with-mll1-r-or-mutant-npm1/ 2025-10-22T19:44:45+00:00 https://cms.syndax.com/publication/men1-mutations-mediate-clinical-resistance-to-menin-inhibition/ 2025-10-22T19:45:47+00:00 https://cms.syndax.com/publication/therapeutic-targeting-of-preleukemia-cells-in-a-mouse-model-of-npm1-mutant-acute-myeloid-leukemia/ 2025-10-22T19:46:13+00:00 https://cms.syndax.com/publication/a-menin-mll-inhibitor-induces-specific-chromatin-changes-and-eradicates-disease-in-models-of-of-mll-rearranged-leukemia/ 2025-10-22T19:46:43+00:00 https://cms.syndax.com/publication/semimechanistic-population-pk-pd-modeling-of-axatilimab-in-healthy-participants-and-patients-with-solid-tumors-or-chronic-graft-versus-host-disease/ 2025-10-22T19:47:22+00:00 https://cms.syndax.com/publication/real-world-treatment-patterns-among-patients-with-relapsed-or-refractory-r-r-npm1-mutated-npm1m-acute-myeloid-leukemia-aml-in-the-united-states-us/ 2025-11-11T17:19:34+00:00 https://cms.syndax.com/publication/revumenib-for-patients-with-relapsed-or-refractory-r-r-nucleophosmin-1-mutated-npm1m-acute-myeloid-leukemia-aml-outcomes-by-prior-treatment-in-the-phase-2-augment-101-study/ 2025-12-07T13:14:45+00:00 https://cms.syndax.com/publication/preliminary-results-of-a-phase-1-study-of-the-safety-and-tolerability-of-the-combination-of-revumenib-rev-with-gilteritinib-gilt-in-relapsed-refractory-r-r-acute-myeloid-leukemia-aml/ 2025-12-07T13:19:24+00:00 https://cms.syndax.com/publication/revumenib-in-combination-with-intensive-induction-and-consolidation-for-newly-diagnosed-patients-with-npm1-mutated-or-kmt2a-rearranged-acute-myeloid-leukemia-preliminary-results-from-the-phase-1b-etc/ 2025-12-08T13:13:54+00:00 https://cms.syndax.com/publication/revumenib-for-patients-with-relapsed-or-refractory-r-r-kmt2ar-acute-leukemia-outcomes-by-leukemia-type-in-the-phase-2-augment-101-study/ 2025-12-08T22:36:08+00:00 https://cms.syndax.com/publication/axatilimab-in-combination-with-ruxolitinib-in-patients-with-newly-diagnosed-chronic-graft-versus-host-disease-interim-safety-analysis-of-a-phase-2-randomized-study/ 2025-12-09T22:57:58+00:00 https://cms.syndax.com/publication/long-term-treatment-duration-and-safety-of-axatilimab-among-patients-with-chronic-graft-versus-host-disease-in-agave-201/ 2025-12-09T22:59:08+00:00 https://cms.syndax.com/publication/phase-1-study-of-revumenib-in-combination-with-intensive-chemotherapy-ic-in-patients-pts-with-newly-diagnosed-nd-acute-myeloid-leukemia-aml-harboring-genetic-alterations-in-kmt2a-npm1-or-nup/ 2025-12-09T23:00:04+00:00 https://cms.syndax.com/publication/phase-ii-study-of-the-all-oral-combination-of-revumenib-sndx-5613-with-decitabine-cedazuridine-astx727-and-venetoclax-save-in-newly-diagnosed-aml/ 2025-12-09T23:01:12+00:00 https://cms.syndax.com/publication/post-transplant-maintenance-with-revumenib-in-children-with-hox-driven-aml/ 2025-12-09T23:02:04+00:00 https://cms.syndax.com/publication/early-real-world-experience-with-revumenib-outside-of-a-clinical-trial-setting-a-single-center-retrospective-review-of-efficacy-and-tolerability/ 2025-12-09T23:03:35+00:00 https://cms.syndax.com/publication/safety-and-feasibility-of-0-6-mg-kg-every-4-weeks-dosing-of-axatilimab-in-patients-treated-in-the-agave-201-study/ 2025-12-12T22:40:26+00:00 https://cms.syndax.com/publication/trial-in-progress-a-phase-3-randomized-double-blind-placebo-controlled-study-of-axatilimab-and-corticosteroids-as-initial-treatment-for-moderate-to-severe-chronic-graft-versus-host-disease/ 2025-12-12T22:41:34+00:00 https://cms.syndax.com/publication/co-targeting-menin-and-ras-in-kmt2a-r-npm1c-aml-with-activated-rtk-ras-mapk-signaling/ 2025-12-12T22:42:15+00:00 https://cms.syndax.com/publication/a-multicenter-phase-1-trial-evaluating-the-safety-and-preliminary-efficacy-of-revumenib-as-post-transplant-maintenance-after-allogeneic-hematopoietic-cell-transplant-in-patients-with-kmt2a-rearranged/ 2025-12-12T22:42:58+00:00 https://cms.syndax.com/publication/phase-1b-2-study-of-axatilimab-in-combination-with-azacitidine-in-advanced-phase-mpn-mds-mpn-overlap-and-high-risk-cmml/ 2025-12-12T22:43:46+00:00 https://cms.syndax.com/publication/safety-analysis-of-axatilimab-in-patients-with-chronic-graft-versus-host-disease-in-an-expanded-access-program/ 2025-12-12T22:44:54+00:00 https://cms.syndax.com/publication/csf-1r-inhibition-and-lenalidomide-synergize-to-promote-myeloma-control-after-autologous-stem-cell-transplantation/ 2025-12-12T22:45:21+00:00 https://cms.syndax.com/publication/single-cell-transcriptomic-studies-reveal-altered-heterogeneity-in-cd41-enriched-megakaryocytes-after-targeted-therapy-in-myeloproliferative-neoplasms/ 2025-12-12T22:46:26+00:00 https://cms.syndax.com/publication/real-world-treatment-patterns-and-outcomes-among-patients-with-newly-diagnosed-npm1-mutated-acute-myeloid-leukemia-in-the-united-states/ 2025-12-12T22:47:06+00:00 https://cms.syndax.com/publication/csf1r-csf1-axis-blockade-with-axatilimab-effectively-targets-leukemia-stem-cells-and-monocytes-in-aml-resistant-to-bh3-mimetics/ 2025-12-12T22:47:41+00:00 https://cms.syndax.com/publication/menin-inhibition-as-a-new-therapeutic-option-for-the-myeloproliferative-neoplasms/ 2025-12-12T22:48:21+00:00 https://cms.syndax.com/publication/clinical-and-disease-characteristics-of-initial-participants-at-time-of-enrollment-in-thrive-a-prospective-observational-cohort-study-of-patients-at-risk-for-chronic-graft-versus-host-disease/ 2025-12-12T22:48:53+00:00 https://cms.syndax.com/publication/pharmacodynamic-analysis-of-agave-201-indicates-changes-in-csf-1r-expressing-cells-and-associated-biomarkers-potentially-contributing-to-chronic-graft-versus-host-disease-resolution/ 2025-12-12T22:49:38+00:00 https://cms.syndax.com/publication/the-menin-inhibitor-revumenib-in-kmt2a-rearranged-or-npm1-mutant-leukaemia/ 2026-04-02T21:28:51+00:00